Clinical Trial

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a randomized, investigator-and-participant-blind, placebo-controlled, fixed sequence, cross-over, Phase 1 study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of orally administered RO7795081 and the effect of a steady-state dose of orally administered RO7795081 on the pharmacokinetics of pitavastatin and rosuvastatin in otherwise healthy, overweight or obese adult participants.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2025-05-13; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-10
Trial Details
NCT Number NCT06982131
Lead Sponsor Hoffmann-La Roche
Conditions Overweight, Obesity
Enrollment 40 participants
Start Date 2025-06-04
Primary Completion 2026-12-04 (estimated)
Study Completion 2026-12-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-05